RxDoctor Payments Data

Hassan Asghar, DO

Internal Medicine · Georgetown, TXNPI 1851898704

Payments from drug & device makers

$1,464in general payments, 2019–2025

Across 80 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$340
  • Lilly USA, LLC$226
  • Pfizer$149
  • Dexcom, Inc.$131
  • Amgen$130
  • GSK$108
  • plus $379 from 13 others

What the payments were for

  • Food & beverage$1,464100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,464 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$117,062
Medicare patients
322
Services billed
1,588

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide121$162,123
OzempicSemaglutide90$102,321
TrulicityDulaglutide74$97,930
JanuviaSitagliptin Phosphate63$72,552
EliquisApixaban48$55,083
JardianceEmpagliflozin36$46,430
JulucaDolutegravir/Rilpivirine11$44,887
Budesonide ErBudesonide19$43,866
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$40,987
RybelsusSemaglutide12$25,544
LinzessLinaclotide17$20,748
MyrbetriqMirabegron19$15,631
Spiriva RespimatTiotropium Bromide15$14,715
XareltoRivaroxaban14$14,527
Repatha SureclickEvolocumab19$10,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$226$260,053195 claims
Novo NordiskOzempic, Rybelsus$340$127,865102 claims
MerckJanuvia$14$72,55263 claims
Boehringer IngelheimJardiance, Spiriva Respimat$43$61,14551 claims
PfizerEliquis$149$55,08348 claims
GSKTrelegy Ellipta$108$40,98761 claims
AbbVieLinzess$14$20,74817 claims
Astellas Pharma US IncMyrbetriq$23$15,63119 claims
Sanofi-aventis U.S. LLCLantus$18$2,68439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Georgetown

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →